On December 26th 2023, AbbVie announced that it will acquire Massachusetts based biotech Cerevel Therapeutics for $45.00 per share. The transaction represents an equity value
AbbVie has agreed to acquire cancer biotech ImmunoGen (IMGN) for $10.1 billion in an all cash offering for $31.26 per share. J.P Morgan and Morgan
Suppose you were teleported to Copenhagen, Denmark this instant. A look around would yield a scene far different from what we are accustomed to in
There has been an encouraging trend in the life science industry, a growing emphasis on rare diseases. Where as little as 20 years ago, there
